PCSK9

heart cardiovascular check up stethescope

Biotech

AZ's oral PCSK9 inhibitor halves bad cholesterol in phase 2

AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks at its highest dose, hitting the goal of a phase 2 trial.

James Waldron Mar 31, 2025 12:00pm

Graphic of someone in a boat navigating the rise and fall of different data riding data plots like a wave

Verve halts VERVE-101 enrollment, focuses on 2nd PCSK9 editor

Apr 2, 2024 7:00am

start line beginning road path starting point journey

Merck bets big on oral PCSK9 inhibitor with phase 3 program

Aug 25, 2023 8:35am

germ line gene editing DNA pass down family tree inherit

FDA hands Verve list of demands for lifting gene editing hold

Dec 5, 2022 9:20am

AstraZeneca dumps drug despite hit in phase 2 cholesterol trial

Sep 23, 2022 5:23am

Vertex

Vertex puts up $60M to partner on in vivo gene editing program

Jul 21, 2022 9:10am